Difference between revisions of "Rhabdomyosarcoma"
Jump to navigation
Jump to search
m (→IHC: sm fix.) |
(→IHC: more) |
||
| Line 87: | Line 87: | ||
*Myogenin. | *Myogenin. | ||
===Subtyping via IHC<ref name=PST14feb11>PST. 14 February 2011.</ref>=== | ===Subtyping via IHC=== | ||
PST proposes<ref name=PST14feb11>PST. 14 February 2011.</ref> the following (presumably based on Makawitz et al.<ref name=pmid18788888>{{cite journal |author=Makawita S, Ho M, Durbin AD, Thorner PS, Malkin D, Somers GR |title=Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors |journal=Pediatr. Dev. Pathol. |volume=12 |issue=2 |pages=127–35 |year=2009 |pmid=18788888 |doi=10.2350/08-05-0477.1 |url=}}</ref>): | |||
{| class="wikitable sortable" style="margin-left:auto;margin-right:auto" | {| class="wikitable sortable" style="margin-left:auto;margin-right:auto" | ||
| '''IHC''' | | '''IHC''' | ||
| Line 114: | Line 115: | ||
| +ve | | +ve | ||
|} | |} | ||
A paper bu Wachtel at al.<ref>{{cite journal |author=Wachtel M, Runge T, Leuschner I, ''et al.'' |title=Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry |journal=J. Clin. Oncol. |volume=24 |issue=5 |pages=816–22 |year=2006 |month=February |pmid=16391296 |doi=10.1200/JCO.2005.03.4934 |url=}}</ref> proposes the use of: | |||
* ''AP2beta'' and ''P-cadherin'' +ve in translocation positive alveolar RMS, and | |||
* ''EGFR'' and ''fibrillin-2'' +ve in embryonal RMS and translocation negative alveolar RMS. | |||
==[[Electronmicroscopy]]== | ==[[Electronmicroscopy]]== | ||
Revision as of 21:52, 9 March 2011
Rhabdomyosarcoma, often abbreviated RMS, is a malignant tumour of skeletal muscle.
General
- Most common paediatric sarcoma.
- ~6% of all childhood cancer.
Classification
Histologic
- Alveolar rhabdomyosarcoma.
- Usually young adults/adolescents.
- Early mets common.
- Usu. arises in regions with skeletal muscle.
- Embryonal rhabdomyosarcoma.
- Usual <10 years old.
- Typically locally invasive.
- Usu. arises in regions without skeletal muscle.
Molecular and histologic
- Translocation-positive alveolar RMS.
- Translocation-negative alveolar RMS.
- Embryonal RMS.
Notes:
- Translocation-negative alveolar RMS shares gene expression prolifing characteristics with embryonal RMS -- suggesting these can be grouped together.
Microscopic
Alveolar rhabdomyosarcoma
Features:[1]
- Alveolus-like pattern -- key low-power feature.
- Fibrous septae lined by tumour cells.
- Cells may "fall-off" the septa, i.e. be detached/scattered in the alveolus-like space.
- Space between fibrous sepate may be filled with tumour = solid variant of alveolar rhabdomyosarcoma.
- Fibrous septae lined by tumour cells.
- Rhabdomyoblasts - essentially diagnostic.
- Eccentric nucleus.
- Moderate amount of intensly eosinophilic cytoplasm.
- Striations -- if you're really lucky; these are not common.
Other features:
- Nuclear pleomorphism - common.
- Mitoses - common.
Notes:
- Well-differentiated rhabdomyoblasts are uncommon in alveolar RMS.
Embryonal rhabdomyosarcoma
Features:[1]
- Randomly arranged small cells.
- Myxoid matrix.
- Strap cells:
- Tadpole-like morphology.
- Rhabdomyoblasts - essentially diagnostic.
- Eccentric nucleus.
- Moderate amount of intensly eosinophilic cytoplasm.
- Striations -- if you're really lucky; these are not common.
Subtypes of embryonal RMS
There are two common subtypes of embryonal RMS. Both of them have a better prognosis that embryonal RMS not otherwise specified (NOS).
Common subtypes:
- Botryoid subtype:
- Gross: Grape-like morphology.
- Microscopic: Non-proliferating layer deep to the surface ("Cambrian layer").
- Spindle cell subtype.
- General: may mimic leiomyosarcoma -- which is not common in the pediatric population.
- Microscopic: vesicular growth pattern, spindle cells.
Anaplasia
Criteria:
- Hyperchromatic nuclei with size variation greater or equal to 3x.
- Multipolar (atypical) mitotic figures.
Subclassification:
- Focal - a few cells.
- Diffuse - cluster or sheets of anaplasia.
Notes:
- Not subtle - can identify at low power.
- Seen in 10-15% of RMS.
- More common in older individuals.
- Poorer prognosis in embryonal RMS.
- No change in prognosis in alveolar RMS.
IHC
Panel of muscle markers -- DAM:
- Desmin (best marker).
- Actin.
- Myogenin.
Subtyping via IHC
PST proposes[1] the following (presumably based on Makawitz et al.[2]):
| IHC | Translocation positive alveolar RMS |
Embryonal RMS | Translocation negative alveolar RMS |
| myogenin | +ve -- diffuse | +ve -- focal | +ve -- diffuse |
| EGFR | -ve | +ve | -ve |
| P-cadherin | +ve | -ve | -ve |
| IGF2 | -ve | +ve | +ve |
A paper bu Wachtel at al.[3] proposes the use of:
- AP2beta and P-cadherin +ve in translocation positive alveolar RMS, and
- EGFR and fibrillin-2 +ve in embryonal RMS and translocation negative alveolar RMS.
Electronmicroscopy
Features:
- Sarcomeric like structures - usu. in "bent" cells; cells that are U-shaped.
Molecular diagnostics
Alveolar rhabdomyosarcoma
Common translocations (~80%):
- t(1,13).
- PAX7/FKHR fusion gene.
- t(2,13).[4]
- PAX3/FKHR fusion gene.
Notes:
- t(1,13) vs. t(2,13) -- t(1,13) usually: younger age, extremity lesion, localized disease, better survival.
- Several uncommon translocations exist.
See also
References
- ↑ 1.0 1.1 1.2 PST. 14 February 2011.
- ↑ Makawita S, Ho M, Durbin AD, Thorner PS, Malkin D, Somers GR (2009). "Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors". Pediatr. Dev. Pathol. 12 (2): 127–35. doi:10.2350/08-05-0477.1. PMID 18788888.
- ↑ Wachtel M, Runge T, Leuschner I, et al. (February 2006). "Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry". J. Clin. Oncol. 24 (5): 816–22. doi:10.1200/JCO.2005.03.4934. PMID 16391296.
- ↑ URL: http://www.ncbi.nlm.nih.gov/omim/606597. Accessed on: 18 August 2010.